Swarthmore Group Inc. decreased its position in shares of Pfizer Inc. (NYSE: PFE – Get Rating) by 0.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 122,500 shares of the biopharmaceutical company stock after selling 1,133 shares during the quarter. Pfizer accounts for 1.6% of Swarthmore Group Inc.’s portfolio, making the stock its 17th largest position. Swarthmore Group Inc.’s holdings in Pfizer were worth $ 6,342,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. State Street Corp boosted its holdings in Pfizer by 1.8% in the fourth quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company stock worth $ 16,818,434,000 after purchasing an additional 5,013,651 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Pfizer by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company stock worth $ 5,952,333,000 after purchasing an additional 1,471,980 shares during the last quarter. Norges Bank purchased a new stake in Pfizer in the fourth quarter worth approximately $ 3,351,891,000. Morgan Stanley boosted its holdings in Pfizer by 3.4% in the second quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company stock worth $ 1,875,532,000 after purchasing an additional 1,582,052 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its holdings in Pfizer by 18.0% in the fourth quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company stock worth $ 1,658,518,000 after purchasing an additional 4,278,167 shares during the last quarter. Hedge funds and other institutional investors own 66.50% of the company stock.
In related news, SVP Jennifer B. Damico sold 4,218 shares of Pfizer stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $ 53.96, for a total transaction of $ 227,603.28. Following the completion of the transaction, the senior vice president now directly owns 10,846 shares of the company stock, valued at approximately $ 585,250.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of Pfizer stock in a transaction dated Thursday, May 12th. The stock was sold at an average price of $ 50.00, for a total transaction of $ 1,645,400.00. Following the transaction, the executive vice president now directly owns 38,146 shares of the company stock, valued at $ 1,907,300. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock valued at $ 2,075,003 over the last three months. Corporate insiders own 0.05% of the company stock.
Shares of NYSE PFE opened at $ 48.11 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The company has a market cap of $ 269.94 billion, a P / E ratio of 11.03, a P / E / G ratio of 0.56 and a beta of 0.76. The firm’s fifty day moving average is $ 50.65 and its two-hundred day moving average is $ 52.24. Pfizer Inc. has a 52-week low of $ 38.82 and a 52-week high of $ 61.71.
Pfizer (NYSE: PFE – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $ 1.66 by ($ 0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company had revenue of $ 25.66 billion during the quarter, compared to the estimate consensus of $ 24.73 billion. During the same quarter in the prior year, the firm posted $ 0.93 earnings per share. The business’s revenue was up 76.8% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 6.61 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were paid a $ 0.40 dividend. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $ 1.60 dividend on an annualized basis and a dividend yield of 3.33%. Pfizer’s payout ratio is currently 36.70%.
Several brokerages have recently weighed in on PFE. Berenberg Bank set a $ 50.00 price target on shares of Pfizer in a research note on Friday, May 27th. Barclays set a $ 52.00 price target on shares of Pfizer in a research note on Tuesday, May 17th. The Goldman Sachs Group set a $ 51.00 price target on shares of Pfizer in a research note on Wednesday, May 25th. Wells Fargo & Company decreased their price objective on shares of Pfizer from $ 60.00 to $ 55.00 in a research report on Wednesday, May 4th. Finally, JPMorgan Chase & Co. set a $ 57.00 price objective on shares of Pfizer in a research report on Tuesday, May 3rd. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $ 57.26.
Pfizer Company Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE: PFE – Get Rating).
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.